Biomedical Engineering Reference
In-Depth Information
previously untreated chronic hepatitis C virus infection.
N. Engl. J. Med. 364(25), 2405-2416.
95. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacob-
son IM, Afdhal NH, et al. (2011) Telaprevir for previously
treated chronic HCV infection. N. Engl. J. Med. 362(14),
1292-1303.
96. Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S,
Grander D. (1997) Induction of apoptosis and inhibition of
cell growth are independent responses to interferon-alpha in
hematopoietic cell lines. Cell Growth Differ. 8(3), 343-352.
97. Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K,
Sangfelt O, Castro J, et al. (2002) Mechanisms of Inter-
feron-alpha induced apoptosis in malignant cells. Oncogene
21(8), 1251-1262.
98. Sidky YA, Borden EC. (1987) Inhibition of angiogenesis by
interferons: effects on tumor- and lymphocyte-induced vas-
cular responses. Cancer Res. 47(19), 5155-5161.
99. Indraccolo S. (2010) Interferon-alpha as angiogenesis inhibitor:
learning from tumor models. Autoimmunity 43(3), 244-247.
100. Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B,
Schreiber RD, et al. (2007) Type I IFN contributes to NK cell
homeostasis, activation, and antitumor function. J. Immunol.
178(12), 7540-7549.
101. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher
MF. (2005) Type I IFNs provide a third signal to CD8 T cells
to stimulate clonal expansion and differentiation. J. Immunol.
174(8), 4465-4469.
102. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-
Spotloe J, Smelko B, et al. (2002) Mechanisms and manage-
ment of toxicities associated with high-dose interferon alfa-
2b therapy. J. Clin. Oncol. 20(17), 3703-3718.
103. Jonas A, von Eckardstein A, Kezdy KE, Steinmetz A,
Assmann G. (1991) Structural and functional properties
of reconstituted high density lipoprotein discs prepared
with six apolipoprotein A-I variants. J. Lipid Res. 32(1),
97-106.
104. Bruckert E, von Eckardstein A, Funke H, Beucler I, Wiebusch
H, Turpin G, et al. (1997) The replacement of arginine by
cysteine at residue 151 in apolipoprotein A-I produces
a phenotype similar to that of apolipoprotein A-IMilano.
Atherosclerosis 128(1), 121-128.
105. Franceschini G, Sirtori CR, Capurso A, 2nd, Weisgraber KH,
Mahley RW. (1980) A-IMilano apoprotein. Decreased high
density lipoprotein cholesterol levels with significant lipo-
protein modifications and without clinical atherosclerosis in
an Italian family. J. Clin. Invest. 66(5), 892-900.
Search WWH ::
Custom Search